|

Deucravacitinib for Patients With Moderate/Severe Psoriasis: A Real-Life Experience in Italy

RECRUITINGSponsored by Bristol-Myers Squibb
Actively Recruiting
SponsorBristol-Myers Squibb
Started2025-08-05
Est. completion2027-07-05
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07256015

Summary

The purpose of this study is to characterize the real-life experience of patients with moderate/severe psoriasis receiving deucravacitinib treatment, in terms of efficacy, safety, and health-related quality of life (HRQoL) in Italy

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Participants have initiated treatment with deucravacitinib monotherapy 4 to 8 weeks earlier according to clinical practice and to reimbursement criteria determined by National Drug Agency in Italy (AIFA)
* Patients have moderate to severe plaque psoriasis
* Patients have signed informed consent form (ICF)

Exclusion Criteria:

* Simultaneous participation in any interventional study for their moderate-to-severe psoriasis
* Inability to participate to the study for the following reasons: patients unable to understand the aim of the study, patients unable to understand and sign the ICF

Conditions2

CancerPsoriasis

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.